Medication combo to prevent GVHD after stem cell transplant
Part of Immune system & allergy clinical trials.
This study tests a new combination of medications (post-transplant cyclophosphamide, bortezomib, and sitagliptin) to prevent graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to improve the safety and success of the transplant for people with blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have a blood cancer like acute leukemia, myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)
- You need a matched sibling or unrelated donor for a stem cell transplant
- Your heart, kidneys, and lungs must be working well enough to handle the transplant
- You cannot have certain active infections (like HIV) or be pregnant or nursing
- You must not have had a previous stem cell transplant or certain other cancers in the last few years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medicines (post-transplant cyclophosphamide, bortezomib, and abatacept) to lower your chance of developing graft-versus-host disease (when transplanted immune cells attack your body) after a transplant. If you qualify, you’ll receive the study medicines as part of your post-transplant care and be followed closely to check safety and prevention of GvHD.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This study tests a combination of three drugs (cyclophosphamide, sirolimus, and VIC-1911) to prevent graft-versus-host disease (GVHD), a common complication after a stem cell transplant. It is for children aged 8-18 with certain blood diseases who are undergoing a haploidentical stem cell transplant.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
Hear when a new GVHD - Graft-Versus-Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.